Is 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione? Is 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione safe for nursing mother and child? Does 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione extracts into breast milk? Does 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione has any long term or short term side effects on infants? Can 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione influence milk supply or can 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione decrease milk supply in lactating mothers?
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione lactation summary
- DrLact safety Score for 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione .
- Usage of 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione is in contradiction to breastfeeding hence if it is must to use 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione usage in lactation
Drug is cleared from the body in 3-5 elimination half-lives. Resuming breastfeeding is likely safe after 2 - 3 months of of pumping-and-dumping.
Answer by DrLact: About 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione usage in lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, such as 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione.[1][2] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear. In one patient, 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione was still detectable in milk 28 days after a dose of 6 mg per square meter. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[3] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[4]
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione Side Effects in Breastfeeding
One mother received 3 daily doses of 6 mg/sq m of 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione intravenously along with 5 daily doses of etoposide 80 mg/sq m and cytarabine 170 mg/sq m intravenously. She resumed breastfeeding her infant 3 weeks after the third dose of 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione at a time when 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione was still detectable in milk. The infant had no apparent abnormalities at 16 months of age.[3]
Alternate Drugs
Dasatinib(Unsafe)
Exemestane(Dangerous)
Vincristine(Dangerous)
Nilotinib(Unsafe)
Tamoxifen(Dangerous)
Mitoxantrone(Dangerous)
Dactinomycin(Dangerous)
Ipilimumab(Unsafe)
Mercaptopurine(Safe)
Cetuximab(Unsafe)
Carboplatin(Dangerous)
Hydroxyurea(Low Risk)
Paclitaxel(Dangerous)
Etoposide(Dangerous)
Fluorouracil(Dangerous)
Nivolumab(Unsafe)
Doxorubicin(Dangerous)
Gemcitabine(Dangerous)
Alemtuzumab(Low Risk)
Vinblastine(Dangerous)
Cyclophosphamide(Dangerous)
Rituximab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Cisplatin(Unsafe)
Bevacizumab(Low Risk)
Vinorelbine(Dangerous)
Busulfan(Dangerous)
Pazopanib(Unsafe)
Dacarbazine(Dangerous)
Trastuzumab(Unsafe)
Imatinib(Unsafe)
Thioguanine(Dangerous)
Cladribine(Dangerous)
Azelaic Acid(Safe)
Erlotinib(Unsafe)
Letrozole(Dangerous)